Stuart Orkin, MD

IRM Awards 3rd Elaine Redding Brinster Prize to Stuart Orkin, MD

Recognized for landmark discoveries of the molecular basis of blood disorders and using the basic science findings for therapeutic approaches, the Institute for Regenerative Medicine at the University of Pennsylvania has awarded Stuart H. Orkin, MD the third Elaine Redding Brinster Prize in Science or Medicine. He elucidated the mechanism controlling the switch from fetal to adult hemoglobin, and reduced to practice reactivation of fetal hemoglobin as a therapeutic strategy for sickle cell disease and other blood cell disorders.

“Dr. Orkin has beautifully illustrated how a career of basic science investigation into the mechanisms for gene regulation can be applied, in one’s own laboratory, to a method for combating devastating human diseases. Notably, his discovery of unexpected details in how the fetal hemoglobin gene is regulated suggested insights for a therapy, for which he availed of the latest gene editing technologies to develop a specific clinical application for sickle cell disease,” said Ken Zaret, PhD, director of Penn’s Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology in the Perelman School of Medicine. “We are thrilled that Dr. Orkin is the third awardee of the Elaine Redding Brinster Prize.”

The prize, supported by an endowment from the children of Elaine Redding Brinster, is awarded annually to a researcher whose singular discovery has made a unique impact on biomedicine. Each winner receives $100,000, a commemorative medal, and an invitation to present a ceremonial lecture at the University of Pennsylvania.

Orkin will accept the prize March 13, 2024, as part of the day-long Ralph L. Brinster Symposium. The symposium will feature several eminent speakers from across the biomedical sciences, including Titia de Lange, PhD, of the Rockefeller University; Carla Shatz, PhD, of Stanford University; Alejandro Sànchez Alvarado, PhD, of the Stowers Institute for Medical Research; and Marianne Bronner, PhD, of the California Institute of Technology.

Read more in Penn Medicine News

IRM Awards 2nd Elaine Redding Brinster Prize to Huda Zoghbi

For her work pinpointing the underlying, genetic causes of a pair of devastating neurological diseases, the Institute for Regenerative Medicine at the University of Pennsylvania awarded Huda Zoghbi, MD the second Elaine Redding Brinster Prize in Science or Medicine. Zoghbi’s research advanced the field’s conceptual understanding of how gene expression can influence neurological health, even in non-inherited disorders.

“Dr. Zoghbi’s interests in the basis for neurological disorders were sparked by her initial observations in the clinic. It was an exceptional path from there to revealing how mutations in a methyl-DNA binding protein cause Rett’s syndrome and how expansion of DNA repeat sequences cause spinocereballar ataxia 1,” said Ken Zaret, PhD, director of the Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology. “We are thrilled that Dr. Zoghbi is the second awardee of the Elaine Redding Brinster Prize.”

The prize, supported by an endowment from the children of Elaine Redding Brinster, is awarded annually to a researcher whose singular discovery has made a unique impact on biomedicine. Each winner receives $100,000, a commemorative medal, and an invitation to present a ceremonial lecture at the University of Pennsylvania.

Zoghbi will accept the prize March 15, 2023, as part of the day-long Ralph L. Brinster Symposium. The symposium will feature several eminent speakers from across the biomedical sciences, including Janet Rossant, PhD, of the University of Toronto, Lynne Maquat, PhD, of the University of Rochester, Karl Deisseroth, MD, PhD, of Stanford University, and Lorenz Studer, MD, of Memorial-Sloan Kettering.

Read more in Penn Medicine News

 

Inaugural Elaine Redding Brinster Prize Awarded to Scientist Who Sparked Growth of Epigenetics

The Institute for Regenerative Medicine the University of Pennsylvania has awarded C. David Allis, PhD, an American molecular biologist, with the inaugural Elaine Redding Brinster Prize in Science or Medicine. Allis’ research helped spark the field of epigenetics, which is the study of how a person’s behavior and environment can change the way their genes operate. Epigenetics now yield useful insights on everything from what may cause seizures to how bodies age and the way chronic diseases develop and progress.

“We are thrilled to award this honor for the first time to Dr. Allis, whose foundational biochemical discoveries have impacted so many aspects of biology and medicine,” said Ken Zaret, PhD, director of the Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology. “It’s a timely way to highlight the importance of science to society.”

The prize, supported by an endowment from the children of Elaine Redding Brinster, will be awarded annually to a researcher whose singular discovery has made a unique impact on biomedicine. Each winner will receive $100,000, a commemorative medal, and an invitation to present a ceremonial lecture to the University of Pennsylvania campus community.

Allis will accept the prize March 16, 2022, as part of the daylong Ralph L. Brinster Symposium.

Read more in Penn Medicine News.